Tealwood Asset Management Inc Incyte Corp Transaction History

Tealwood Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$56.55 - $66.59 $8,312 - $9,788	-147 Reduced 0.83%	17,483 $996,000
Q4 2023 Jan 08, 2024	BUY	$52.16 - $64.19 $273,840 - $336,997	5,250 Added 42.41%	17,630 $1.11 Million
Q3 2023 Nov 08, 2023	SELL	$57.77 - $65.93 $9,300 - $10,614	-161 Reduced 1.28%	12,380 $715,000
Q2 2023 Jul 26, 2023	SELL	$60.95 - $75.51 $3,961 - $4,908	-65 Reduced 0.52%	12,541 $781,000
Q1 2023 Apr 12, 2023	BUY	$70.23 - $86.01 $885,319 - $1.08 Million	12,606 New	12,606 $911,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Tealwood Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Tealwood Asset Management Inc with notifications on news.